Izindaba Zemboni
Ukusebenza Kwesikhathi Eside Kwe-CD19 CAR T-Cell Therapy ekwelapheni I-Relapsed/Refractory Acute Lymphoblastic Leukemia
Ucwaningo olubalulekile lubonisa impumelelo yesikhathi eside yokwelashwa kwe-CD19 CAR T-cell ekwelapheni iziguli ezine-acute lymphoblastic leukemia (ALL) ebuyele emuva/esabelayo elandela ukufakelwa kwe-allogeneic hematopoietic stem cell, okunikeza ithemba elisha ku-hematology.
Intuthuko Ethuthukile Kumaseli Okubulala Wemvelo (NK) Ngaphezu kweminyaka engama-50
Emashumini amahlanu eminyaka adlule, ucwaningo lwamangqamuzana Okubulala Kwemvelo (NK) lwenze ushintsho ekuqondeni kwethu ukungatheleleki okungokwemvelo, okunikeza izindlela ezintsha ezithembisayo zomdlavuza kanye nokwelapha ngegciwane.
Ukuphumelela Kwezifo Ezizenzakalelayo Zezingane: I-CAR-T Cell Therapy Yelapha Isiguli Se-Lupus
Ucwaningo oluphambili eSibhedlela sase-Erlangen University lwelaphe ngempumelelo intombazane eneminyaka engu-16 ubudala ene-systemic lupus erythematosus (SLE) enzima kusetshenziswa ukwelashwa kweseli ye-CAR-T. Lokhu kuphawula ukusetshenziswa kokuqala kwalokhu kwelashwa kwe-lupus yezingane, okunikeza ithemba elisha ezinganeni ezinezifo ezizimele.
Ukuthuthukisa Ukusebenza Kwe-PROTAC: Ucwaningo Oluyisisekelo
Ucwaningo lwakamuva ku-Nature Communications lwembula imininingwane ebalulekile ezindleleni zokusayina zangaphakathi ezilungisa ukuphumelela kokuwohloka kwamaprotheni okuhlosiwe kusetshenziswa ama-PROTAC. Lokhu kutholakala kungavula indlela yokwelashwa okusebenzayo komdlavuza nezinye izifo.
Ukukhuthaza Impilo Nokululama: Ukunakekelwa Kwansuku Zonke Kweziguli Ze-Leukemia
Ukuqinisekisa ukwelashwa okuphephile nokunethezekile kweziguli ze-leukemia kuhilela ukunakekelwa ngokucophelela kwansuku zonke, okuhlanganisa ukukhucululwa kwemvelo, ukuhlanzeka komuntu siqu, ukudla okunomsoco, nokuzivocavoca okufanele. Lo mhlahlandlela unikeza izeluleko ezibalulekile zokunakekelwa kwansuku zonke okusebenzayo ukusekela ukululama.
Imiphumela Eyisisekelo Ye-CD7-Targeted CAR-T Therapy ye-T-ALL ne-T-LBL
Ucwaningo lwakamuva lugqamisa imiphumela ethembisayo ye-CD7-targeted chimeric antigen receptor (CAR) T cell therapy ekwelapheni iziguli ezine-T-cell acute lymphoblastic leukemia (T-ALL) ne-T-cell lymphoblastic lymphoma (T-LBL) ebuyele emuva noma ephikisayo.
Ukuvezwa komhlangano waminyaka yonke we-ASH wango-2024 kanye Nokuvezwa
Umhlangano Waminyaka Yonke Wama-66 we-American Society of Hematology (ASH) uzoba kusukela ngoDisemba 7-10, 2024, e-San Diego Convention Center, ubonisa ucwaningo oluyisisekelo kanye nentuthuko ku-hematology.
Ithemba Elisha Ekwelapheni Umdlavuza: I-TILs Therapy Emerge as the Next Frontier
Naphezu kwezinselele eziqhubekayo ekuthuthukisweni kwezimboni nasekuhwebeni, ukulinganiselwa kokwelashwa kwe-CAR-T kubhekwana nendlela entsha ethembisayo: Ukwelashwa kwe-Tumor-Infiltrating Lymphocyte (TIL). Le mpumelelo imemezela inkathi entsha ekulweni nezimila eziqinile.
Ingabe Ukwelashwa Kweselula Kuyikusasa Lezifo Ezizenzakalelayo?
Ukwelashwa okuguquguqukayo komdlavuza kungase futhi kukwazi ukwelapha nokusetha kabusha amasosha omzimba ukuze anikeze ukuxolelwa kwesikhathi eside noma mhlawumbe ngisho nokwelapha izifo ezithile ezizimele.
